We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Failure to Report Design Change Lands FDA Warning for Collagen Matrix

Failure to Report Design Change Lands FDA Warning for Collagen Matrix

October 14, 2016

Failure to report a design change and to conduct proper design validation for its porcine xenograft particulate in syringe landed Collagen Matrix an FDA warning letter.

The Oakland, N.J.-based company manufactures collagen-based finished devices for use in oral/maxillofacial, neurosurgery and orthopedic spine surgery.

The Sept. 30 warning letter said the instructions for use for the Zcore porcine xenograft syringe indicate that the porcine material in the syringe is hydrated with osseous coagulum, patient blood or sterile saline by pulling and pushing the syringe stoppers.

The firm conducted a functional assessment study, but no design validation study was conducted to ensure that the product conformed to defined user needs, the letter said.

Complaints indicated that the porcine material in the syringe was difficult to eject, and the firm later removed the product from distribution.

The agency said the product was adulterated because the company didn’t have an approved premarket application or an investigational device exemption. The FDA also said the product was misbranded because the firm failed to notify the agency of modifications before marketing.

Specifically, the firm made significant design changes to the MatrixOss Granules (Zcore porcine xenograft particulate) since its initial 510(k) clearance in July 2014, and “such changes could significantly affect the safety and effectiveness of the device,” the letter said.

The FDA explained that when the agency cleared the product, it was in a plastic jar surrounded by an outer blister package. But packaging the Zcore product in a syringe presents “biocompatibility and sterilization validation concerns,” the FDA said, noting that another 510(k) is required to demonstrate that the polymers used in the syringe applicator don’t give off leachables or extractables that could contaminate the biocompatibility of the materials.

In addition, sterilization validation via a 510(k) is required to demonstrate acceptable sterility assurance for the syringe in new packaging. — Tamra Sami

View today's stories

Medical Devices Inspections and Audits

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • UKflag.jpg

    UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

  • emergency use authorization approved

    Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test

  • FDA clears text

    Vetex Medical’s Thrombectomy Catheter Cleared by FDA

  • 100Bills_flatmoney.gif

    Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing